Member Info for RayPointer

I agree Violindog, money has accelerated the clock.
Take the prime example of the SCIB1 combo trial being delayed for years because of the FDA's refusal to approve the Ichor device. I'm sure, having loads of dosh, would have made Scancell look for alternatives sooner than they did.
What would a large pharma have done in a similar situation? Leant on the FDA?

One of the problems is that the crowd is blindfolded most of the time so we cannot see how close to the goal Scancell are.

Hey Ruck, what is this "tick tick"?

Reminds me of:

What did the Gestapo interrogator say to the clock that went « tick…[pause]…tick…[pause]…tick… »
« We haff VAYS to make you tock! »

To use Inan's terminology
We have "Tick Tock" on a number of fronts.
Each one could lead to an explosion.
For balance, each one could be a damp squib causing a plummet in the SP to 5p at which point bazookas will be fired.

If I just mention one of the Tick Tocks.

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/2811-cicon19-paris-jc.pdf

This is one that is not talked about that much on this BB but IMO it is the most intriguing.

• TSCMs can be found in humans, mice and non-human primates at low frequency (2-4%).
• TSCMs possess higher proliferative, greater survival responses and superior anti-tumour capacity
compared to central memory (TCM) and effector memory (TEM) T cells.
• TSCMs have self-renewal capacity and multipotency, capable of reconstituting the full diversity of
the effector and memory T cell compartments on serial transplantation.
• Clinical exploitation of TSCMs is currently not feasible due to their relative low percentage in the
periphery and lack of robust clinical grade protocols for isolating and expanding these cells.

Look at that last sentence
"Clinical exploitation of TSCMs is currently not feasible due to their relative low percentage in the
periphery and lack of robust clinical grade protocols for isolating and expanding these cells."

Well, Lindy has plans to change all that with mAb 2811.
The conclusions are interesting:

• SSEA-4 is a novel marker for human
and mouse TSCMs.
• 2811 mAb able to identify, isolate and
expand putative TSCM in vitro and in
vivo.
• 2811+ T cells are potential candidates
for genetic manipulation to express
antigen specific TCRs or CARs.
• 2811 is a potential T cell agonistic
mAb

I take this to mean that 2811 can be used in 1 of 2 ways:
1 Promoting Clonal expansion of the stem T Cells as a novel way of combatting cancer cells
or
2 Killing stem T Cells as a novel way of combatting auto-immune diseases.

Good news C7.
Long may it continue :-)

It's about Modi2 if the site is accurate.
From experience, Lindy's presentations are never SP sensitive.

Hi Rigga
I use total adblock
https://www.totaladblock.com/
I downloaded it for free about 2 months ago and, surprisingly, it hasn't yet expired. The only add I now get is for total adblock :-)

I think we are just seeing the difference between of Lindy without money and Lindy with money :-)

to data and deals

That's an impressive list of IIs

Team doom and gloom have had their numbers depleted recently. It's good to see that reinforcements have arrived :-)

not should be "note"

The nucleocapsid protein is highly conserved across all Coronaviruses and this is targeted by Covidity.
So, if Covidity works well on Covid19, it should also have an effect on other Coronaviruses.
The size of the effect can only be measured during clinical trials with other Coronaviruses.
So Covidity is a possible universal vaccine against present and future Coronaviruses. Lindy has not claimed any more than that.
CEPI also not this possibility.

https://cepi.net/news_cepi/going-universal-the-search-for-an-all-in-one-coronavirus-vaccine/

"For example, scientists at the University of Nottingham in the UK are working alongside pharmaceutical company Scancell and Nottingham Trent University to test its COVID-19 vaccine candidate, SN14, which targets both the spike protein as well as the nucleocapsid, or N-protein. By targeting this additional viral structure, which is far less likely to mutate, the vaccine if found safe and effective could work to protect people against COVID-19 irrespective of any mutations to the spike protein and, in theory, could work across other coronaviruses."

Zoom event as I rembember

We should just go on what Lindy said at the last AGM when the intention was to complete the Covidity trial and then publish the results some 6 weeks after the completion.
However, you never know, she may give an indication of how things are going at the next AGM. That may also apply to the other 2 trials.

It could be that Boris, having more spare time, has taken up photo editing as a hobby.

Yes, I was touched by that post as well.
My wife plays the violin so it has given me ideas :-)

mea culpa, no echo, just my strange sense of humour

I hope that doesn't mean we are in for another supply side lecture :-)

I am just amazed at that front page on the Scancell website.

3 trials in progress
3-4 of the Gylcans mAbs at various stages of pre-clinical and Scancell will be seeking deals when pre-clinical is complete
iSCIB1 and iSCIB2 both pre-clinical
Modi2 preclinical

and then it is out of date since bispecific glycan mAbs are to be moved into the clinic.
This is truly amazing for a company of the size of Scancell